GlobeNewswire: Adamas Pharmaceuticals, Inc. Contains the last 10 of 203 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T04:48:24ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/01/13/2158021/0/en/Adamas-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2020-Total-Revenues-and-Key-Business-Drivers-for-2021.html?f=22&fvtc=4&fvtv=22927Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 20212021-01-13T14:15:00Z<![CDATA[-- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 ---- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 --]]>https://www.globenewswire.com/news-release/2021/01/07/2155291/0/en/Adamas-to-Present-at-Upcoming-ICR-Conference.html?f=22&fvtc=4&fvtv=22927Adamas to Present at Upcoming ICR Conference2021-01-07T23:02:51Z<![CDATA[EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the ICR Conference 2021, being held January 11-14, 2021.]]>https://www.globenewswire.com/news-release/2021/01/05/2153573/0/en/Adamas-Completes-Acquisition-of-OSMOLEX-ER.html?f=22&fvtc=4&fvtv=22927Adamas Completes Acquisition of OSMOLEX ER®2021-01-05T14:15:00Z<![CDATA[Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition]]>https://www.globenewswire.com/news-release/2021/01/04/2152955/0/en/Adamas-to-Present-at-Upcoming-H-C-Wainwright-Conference.html?f=22&fvtc=4&fvtv=22927Adamas to Present at Upcoming H.C. Wainwright Conference2021-01-04T21:15:00Z<![CDATA[EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright VIRTUAL BioConnect Conference, being held January 11 – 14, 2021.]]>https://www.globenewswire.com/news-release/2020/12/11/2144040/0/en/Adamas-Announces-New-Employment-Inducement-Grant.html?f=22&fvtc=4&fvtv=22927Adamas Announces New Employment Inducement Grant2020-12-11T21:02:00Z<![CDATA[EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 28,500 shares of the company’s common stock, at a per share exercise price of $4.88, the closing trading price on December 7, and restricted stock units to acquire 14,250 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.]]>https://www.globenewswire.com/news-release/2020/12/02/2138170/0/en/Adamas-Announces-Agreement-to-Amend-Royalty-Backed-Loan-Agreement-with-HealthCare-Royalty-Partners.html?f=22&fvtc=4&fvtv=22927Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners2020-12-02T11:51:00Z<![CDATA[Amended terms will provide added flexibility to help drive the growth of the Company Amended terms will provide added flexibility to help drive the growth of the Company]]>https://www.globenewswire.com/news-release/2020/12/02/2138169/0/en/Adamas-Announces-Agreement-to-Settle-Patent-Litigation-with-Osmotica.html?f=22&fvtc=4&fvtv=22927Adamas Announces Agreement to Settle Patent Litigation with Osmotica2020-12-02T11:50:00Z<![CDATA[As part of this agreement Adamas will acquire the global rights to OSMOLEX ER® As part of this agreement Adamas will acquire the global rights to OSMOLEX ER® ]]>https://www.globenewswire.com/news-release/2020/11/24/2133182/0/en/Adamas-to-Present-at-Upcoming-Evercore-ISI-Conference.html?f=22&fvtc=4&fvtv=22927Adamas to Present at Upcoming Evercore ISI Conference2020-11-24T21:03:00Z<![CDATA[EMERYVILLE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st at 11:45 am Eastern Time (8:45 am Pacific).]]>https://www.globenewswire.com/news-release/2020/11/23/2131940/0/en/Adamas-announces-changes-to-its-Board-of-Directors-with-the-appointment-of-Spyros-Papapetropoulos-and-the-retirement-of-Ivan-Lieberburg.html?f=22&fvtc=4&fvtv=22927Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg2020-11-23T14:15:00Z<![CDATA[EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Spyros Papapetropoulos, MD, PhD, to its Board of Directors. Spyros brings more than 20 years of academic and industry experience with a focus on neurology, and previously held R&D and scientific leadership roles at Acadia, Cavion, Teva, Pfizer, Allergan, and Biogen. Additionally, Adamas announced the retirement of Ivan Lieberburg, MD, PhD from the Adamas board.]]>https://www.globenewswire.com/news-release/2020/11/18/2129617/0/en/Adamas-to-Present-at-Upcoming-Piper-Sandler-Conference.html?f=22&fvtc=4&fvtv=22927Adamas to Present at Upcoming Piper Sandler Conference2020-11-18T21:02:00Z<![CDATA[EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held December 1-3, 2020.]]>